| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2024 | 395 | 4.070 |
Why?
|
| Neoplastic Stem Cells | 9 | 2024 | 161 | 2.590 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2023 | 357 | 2.570 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2023 | 788 | 1.960 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 54 | 1.860 |
Why?
|
| Antineoplastic Agents | 10 | 2024 | 2412 | 1.500 |
Why?
|
| Mutation | 11 | 2024 | 4132 | 1.280 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 260 | 1.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2552 | 1.130 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2024 | 616 | 1.120 |
Why?
|
| Behcet Syndrome | 3 | 2015 | 15 | 1.110 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 299 | 1.030 |
Why?
|
| Clonal Evolution | 3 | 2021 | 15 | 0.980 |
Why?
|
| Cisplatin | 4 | 2024 | 617 | 0.980 |
Why?
|
| Cell Self Renewal | 4 | 2019 | 20 | 0.930 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 181 | 0.890 |
Why?
|
| Vincristine | 2 | 2020 | 112 | 0.840 |
Why?
|
| CD55 Antigens | 2 | 2024 | 21 | 0.830 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 342 | 0.820 |
Why?
|
| Rituximab | 2 | 2020 | 119 | 0.820 |
Why?
|
| Prednisone | 2 | 2020 | 258 | 0.800 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 582 | 0.770 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 1543 | 0.770 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 889 | 0.730 |
Why?
|
| Prognosis | 15 | 2024 | 3773 | 0.730 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 360 | 0.730 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 299 | 0.700 |
Why?
|
| Humans | 52 | 2024 | 89073 | 0.690 |
Why?
|
| Leukemia, Myeloid | 1 | 2021 | 249 | 0.690 |
Why?
|
| Adult | 21 | 2024 | 26508 | 0.640 |
Why?
|
| Splicing Factor U2AF | 1 | 2018 | 5 | 0.620 |
Why?
|
| Genomics | 2 | 2021 | 761 | 0.610 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 37 | 0.600 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 60 | 0.600 |
Why?
|
| Aged | 17 | 2024 | 19078 | 0.580 |
Why?
|
| Leukocyte Count | 1 | 2017 | 223 | 0.570 |
Why?
|
| Neutropenia | 2 | 2015 | 216 | 0.570 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 285 | 0.550 |
Why?
|
| Neoplasms | 4 | 2023 | 3035 | 0.530 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 154 | 0.520 |
Why?
|
| Molecular Biology | 1 | 2016 | 89 | 0.510 |
Why?
|
| Young Adult | 8 | 2024 | 6289 | 0.510 |
Why?
|
| Genes, Reporter | 1 | 2016 | 275 | 0.500 |
Why?
|
| Biological Factors | 1 | 2015 | 18 | 0.500 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 203 | 0.500 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 205 | 0.480 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2014 | 21 | 0.470 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 71 | 0.470 |
Why?
|
| Phenotype | 2 | 2022 | 2439 | 0.470 |
Why?
|
| Middle Aged | 18 | 2024 | 25865 | 0.460 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 763 | 0.460 |
Why?
|
| Male | 23 | 2024 | 42254 | 0.460 |
Why?
|
| Histiocytic Disorders, Malignant | 1 | 2013 | 3 | 0.450 |
Why?
|
| Female | 26 | 2024 | 46014 | 0.440 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 1214 | 0.440 |
Why?
|
| Diabetes Complications | 1 | 2014 | 170 | 0.430 |
Why?
|
| Treatment Outcome | 11 | 2024 | 8203 | 0.430 |
Why?
|
| Genetic Variation | 1 | 2019 | 1371 | 0.430 |
Why?
|
| Adolescent | 8 | 2024 | 9237 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 196 | 0.390 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 2553 | 0.390 |
Why?
|
| Cell Nucleus | 2 | 2024 | 599 | 0.390 |
Why?
|
| Sarcoma | 1 | 2013 | 220 | 0.380 |
Why?
|
| Tumor Microenvironment | 3 | 2020 | 459 | 0.380 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 6777 | 0.370 |
Why?
|
| Bone Marrow | 2 | 2023 | 445 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 859 | 0.350 |
Why?
|
| Immunophenotyping | 2 | 2021 | 217 | 0.350 |
Why?
|
| Dendritic Cells | 1 | 2013 | 442 | 0.340 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2021 | 21 | 0.330 |
Why?
|
| Leukemia | 2 | 2022 | 323 | 0.330 |
Why?
|
| Nanog Homeobox Protein | 3 | 2018 | 7 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 559 | 0.320 |
Why?
|
| Disease Management | 2 | 2020 | 329 | 0.310 |
Why?
|
| Risk Factors | 6 | 2024 | 5466 | 0.280 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1710 | 0.270 |
Why?
|
| Azacitidine | 2 | 2023 | 146 | 0.250 |
Why?
|
| Signal Transduction | 3 | 2023 | 3374 | 0.250 |
Why?
|
| Survival Rate | 2 | 2020 | 1889 | 0.250 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 131 | 0.230 |
Why?
|
| CD47 Antigen | 1 | 2024 | 23 | 0.230 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 48 | 0.230 |
Why?
|
| Retrospective Studies | 5 | 2024 | 9003 | 0.230 |
Why?
|
| bcl-X Protein | 1 | 2023 | 54 | 0.230 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 37 | 0.220 |
Why?
|
| Aniline Compounds | 1 | 2023 | 58 | 0.220 |
Why?
|
| Aminopyridines | 1 | 2023 | 40 | 0.220 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 88 | 0.220 |
Why?
|
| Triazines | 1 | 2023 | 53 | 0.220 |
Why?
|
| Pyrazines | 1 | 2023 | 94 | 0.220 |
Why?
|
| Australia | 1 | 2023 | 101 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 95 | 0.210 |
Why?
|
| Mice, SCID | 3 | 2018 | 261 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 2335 | 0.210 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 204 | 0.200 |
Why?
|
| Histones | 1 | 2024 | 329 | 0.200 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2022 | 29 | 0.200 |
Why?
|
| Lymphoma, T-Cell | 1 | 2022 | 55 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2024 | 317 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 412 | 0.190 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2021 | 34 | 0.190 |
Why?
|
| Chromatin | 1 | 2024 | 397 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 106 | 0.190 |
Why?
|
| Activin Receptors, Type II | 1 | 2020 | 9 | 0.190 |
Why?
|
| Thrombopoietin | 1 | 2020 | 12 | 0.190 |
Why?
|
| Hematinics | 1 | 2020 | 11 | 0.190 |
Why?
|
| Chromosome Aberrations | 2 | 2019 | 390 | 0.190 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 19 | 0.190 |
Why?
|
| Naphthyridines | 1 | 2021 | 27 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 189 | 0.190 |
Why?
|
| Idarubicin | 1 | 2020 | 8 | 0.190 |
Why?
|
| Mutation Rate | 1 | 2021 | 48 | 0.190 |
Why?
|
| Receptors, Fc | 1 | 2020 | 32 | 0.190 |
Why?
|
| Lymphoma | 1 | 2022 | 265 | 0.180 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2021 | 49 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2020 | 66 | 0.180 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 397 | 0.180 |
Why?
|
| Thy-1 Antigens | 1 | 2019 | 16 | 0.180 |
Why?
|
| Adenine | 1 | 2020 | 88 | 0.170 |
Why?
|
| Cytarabine | 1 | 2020 | 219 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 200 | 0.170 |
Why?
|
| Blood Transfusion | 1 | 2020 | 166 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 129 | 0.170 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 848 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 187 | 0.170 |
Why?
|
| Recurrence | 1 | 2022 | 1140 | 0.170 |
Why?
|
| Flow Cytometry | 1 | 2021 | 691 | 0.170 |
Why?
|
| Age Factors | 2 | 2024 | 1867 | 0.170 |
Why?
|
| DNA Damage | 1 | 2021 | 371 | 0.160 |
Why?
|
| Piperidines | 1 | 2020 | 164 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 157 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 565 | 0.160 |
Why?
|
| Animals | 9 | 2024 | 27324 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2023 | 657 | 0.160 |
Why?
|
| Turkey | 2 | 2015 | 21 | 0.160 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2018 | 31 | 0.150 |
Why?
|
| Mice | 6 | 2024 | 11742 | 0.150 |
Why?
|
| Child | 4 | 2024 | 7149 | 0.150 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 39 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 77 | 0.150 |
Why?
|
| Retreatment | 1 | 2017 | 108 | 0.150 |
Why?
|
| Smoking | 1 | 2021 | 620 | 0.140 |
Why?
|
| Apoptosis | 1 | 2023 | 1717 | 0.140 |
Why?
|
| Total Quality Management | 1 | 2016 | 33 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 604 | 0.140 |
Why?
|
| Connexins | 1 | 2018 | 201 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2017 | 298 | 0.140 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 59 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3657 | 0.130 |
Why?
|
| Embryonic Stem Cells | 1 | 2016 | 80 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 152 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1591 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 740 | 0.130 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2015 | 3 | 0.130 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2015 | 8 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 783 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 96 | 0.120 |
Why?
|
| Cadherins | 1 | 2015 | 163 | 0.120 |
Why?
|
| Age of Onset | 1 | 2015 | 312 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 360 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2015 | 147 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1755 | 0.120 |
Why?
|
| Infertility, Male | 1 | 2013 | 24 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 385 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 948 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Immunocompetence | 1 | 2013 | 26 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 330 | 0.110 |
Why?
|
| beta Catenin | 1 | 2015 | 266 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1855 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2013 | 24 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1940 | 0.110 |
Why?
|
| United States | 2 | 2024 | 6957 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 1706 | 0.110 |
Why?
|
| Infertility, Female | 1 | 2013 | 96 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 85 | 0.110 |
Why?
|
| Propranolol | 1 | 2013 | 44 | 0.110 |
Why?
|
| Back Pain | 1 | 2013 | 42 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 48 | 0.110 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 51 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 1768 | 0.110 |
Why?
|
| Hemangioma | 1 | 2013 | 64 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2016 | 447 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2023 | 1652 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 85 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 105 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2018 | 4273 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 308 | 0.100 |
Why?
|
| Clone Cells | 2 | 2023 | 214 | 0.100 |
Why?
|
| Depression | 1 | 2015 | 503 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 261 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1363 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1265 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 443 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1670 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1837 | 0.080 |
Why?
|
| Time Factors | 2 | 2015 | 5320 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1194 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2612 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1662 | 0.070 |
Why?
|
| Philadelphia Chromosome | 1 | 2024 | 41 | 0.060 |
Why?
|
| Thymocytes | 1 | 2023 | 31 | 0.060 |
Why?
|
| Infant | 2 | 2024 | 3147 | 0.060 |
Why?
|
| Methylation | 1 | 2024 | 268 | 0.060 |
Why?
|
| Germ Cells | 1 | 2023 | 130 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2024 | 3717 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2023 | 197 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2023 | 161 | 0.050 |
Why?
|
| Protein Transport | 1 | 2024 | 421 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 470 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 170 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2023 | 165 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 106 | 0.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 132 | 0.050 |
Why?
|
| Uridine | 1 | 2021 | 56 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 344 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 645 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 382 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 443 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 306 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2022 | 519 | 0.050 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 35 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 388 | 0.040 |
Why?
|
| Connexin 26 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Mammary Glands, Human | 1 | 2018 | 24 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 114 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2017 | 39 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1533 | 0.040 |
Why?
|
| Karyotype | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1521 | 0.040 |
Why?
|
| Drug Approval | 1 | 2017 | 66 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 2291 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 135 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 172 | 0.040 |
Why?
|
| Organizational Case Studies | 1 | 2016 | 28 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2017 | 155 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2016 | 20 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 80 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 195 | 0.030 |
Why?
|
| Workload | 1 | 2016 | 129 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 46 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2016 | 309 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 685 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 370 | 0.030 |
Why?
|
| Familial Mediterranean Fever | 1 | 2013 | 4 | 0.030 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2013 | 25 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 449 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1135 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 507 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 127 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 956 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 476 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 372 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 1990 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 309 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1240 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1796 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2399 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 2001 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3443 | 0.010 |
Why?
|